Literature DB >> 9052522

Expression of common gamma chain on peripheral blood mononuclear cells in Crohn's disease.

I Kirman1, O H Nielsen.   

Abstract

Mononuclear cell proliferative response to IL-2 and functional response to IL-4 is disturbed in IBD. The aim of the present study was to verify whether altered expression of the common gamma chain (gamma c) might contribute to this abnormality. The gamma c expression on peripheral blood mononuclear cells was analyzed by flow cytometry using a monoclonal antibody to gamma c. IL-4 binding in association with gamma c expression was assessed using biotinylated IL-4 in two-color flow cytometry. Mean fluorescence of gamma c expression was significantly decreased in active CD patients as compared to inactive CD and healthy controls (P < 0.05). Cell activation as a possible reason for gamma c down-regulation was confirmed using the in vitro stimulated donor cells. In the same system it was shown that down-regulation of gamma c is accompanied by decreased numbers of IL-4 binding cells. In conclusion, a decreased expression of the gamma c on peripheral blood mononuclear cells from CD patients with active disease might have an important pathogenetic significance in this chronic intestinal disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052522     DOI: 10.1023/a:1018830305728

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Distinct regulatory effects of IL-4 and TNF-alpha during CD3-dependent and CD3-independent initiation of human T-cell activation.

Authors:  N K Damle; L V Doyle
Journal:  Lymphokine Res       Date:  1989

2.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.

Authors:  R Essner; K Rhoades; W H McBride; D L Morton; J S Economou
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

3.  Construction of a bispecific antibody reacting with the alpha- and beta-chains of the human IL-2 receptor. High affinity cross-linking and high anti-proliferative efficiency.

Authors:  C Francois; F Boeffard; B Kaluza; U H Weidle; Y Jacques
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

4.  Impairment of ligand binding and growth signaling of mutant IL-2 receptor gamma-chains in patients with X-linked severe combined immunodeficiency.

Authors:  N Ishii; H Asao; Y Kimura; T Takeshita; M Nakamura; S Tsuchiya; T Konno; M Maeda; T Uchiyama; K Sugamura
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

5.  Expression of the IL-2 receptor gamma chain on various populations in human peripheral blood.

Authors:  N Ishii; T Takeshita; Y Kimura; K Tada; M Kondo; M Nakamura; K Sugamura
Journal:  Int Immunol       Date:  1994-08       Impact factor: 4.823

6.  Cloning of the gamma chain of the human IL-2 receptor.

Authors:  T Takeshita; H Asao; K Ohtani; N Ishii; S Kumaki; N Tanaka; H Munakata; M Nakamura; K Sugamura
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

7.  Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes.

Authors:  D L Cheung; P H Hart; G F Vitti; G A Whitty; J A Hamilton
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

8.  Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; U Panzer; R Reinking; A Bouchard; P D Stahl; A Raedler
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

9.  Identification of a distinct low-affinity receptor for human interleukin-4 on pre-B cells.

Authors:  W C Fanslow; M K Spriggs; C T Rauch; K N Clifford; B M Macduff; S F Ziegler; K A Schooley; K M Mohler; C J March; R J Armitage
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

10.  Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.

Authors:  M Noguchi; Y Nakamura; S M Russell; S F Ziegler; M Tsang; X Cao; W J Leonard
Journal:  Science       Date:  1993-12-17       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.